We will enroll 300 migraine patients who are diagnosed according to ICHD3-beta criteria in our study and will use a questionnaire to detect their demographic and clinical features (disease duration, attack frequency, and duration, pain intensity assessed by the visual analogic scale and the results of the migraine disability assessment (MIDAS) test and all the patients will receive Ibuprofen (200-400mg) as a treatment to acute attack and lacosamide (100 mg) as a prophylactic treatment for at least three months and we will assess the change in disease duration, attack frequency, and duration, pain intensity assessed by the visual analogic scale and the results of the migraine disability assessment (MIDAS) test, and we will consider a patient a responder to preventative treatment when there is a ≥50% reduction in the monthly headache days frequency compared to the baseline frequency
Our aim is to study the effect of lacosamide as a preventive treatment of migraine by assessing the change in the disease duration, attack frequency, and duration, pain intensity assessed by visual analogic scale, and The Migraine Disability Assessment Test after 90 days of regular use of 50 mg lacosamide twice daily. in patients diagnosed to have migraine based upon the International Classification of Headache Disorders (ICHD) 3rd edition.